Literature DB >> 30552672

Hereditary breast cancer; Genetic penetrance and current status with BRCA.

Morteza Mahdavi1, Mohammadreza Nassiri1, Mohammad Mahdi Kooshyar2, Masoume Vakili-Azghandi1, Amir Avan3,4,5, Ryan Sandry6, Suja Pillai7, Alfred King-Yin Lam5, Vinod Gopalan6.   

Abstract

The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRCA; breast cancer; germline mutations; hereditary genes

Mesh:

Substances:

Year:  2018        PMID: 30552672     DOI: 10.1002/jcp.27464

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

1.  Opinions and experiences of recontacting patients: a survey of Australasian genetic health professionals.

Authors:  Bhavya Bhupen Vora; Helen Mountain; Cassandra Nichols; Lyn Schofield
Journal:  J Community Genet       Date:  2022-01-11

Review 2.  Breast cancer in the era of precision medicine.

Authors:  Negar Sarhangi; Shahrzad Hajjari; Seyede Fatemeh Heydari; Maryam Ganjizadeh; Fatemeh Rouhollah; Mandana Hasanzad
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

Review 3.  Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.

Authors:  James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-07-29       Impact factor: 2.698

4.  High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing.

Authors:  Anna Kostecka; Tomasz Nowikiewicz; Paweł Olszewski; Magdalena Koczkowska; Monika Horbacz; Monika Heinzl; Maria Andreou; Renato Salazar; Theresa Mair; Piotr Madanecki; Magdalena Gucwa; Hanna Davies; Jarosław Skokowski; Patrick G Buckley; Rafał Pęksa; Ewa Śrutek; Łukasz Szylberg; Johan Hartman; Michał Jankowski; Wojciech Zegarski; Irene Tiemann-Boege; Jan P Dumanski; Arkadiusz Piotrowski
Journal:  NPJ Breast Cancer       Date:  2022-06-29

5.  The role of PPM1D in cancer and advances in studies of its inhibitors.

Authors:  Wenhong Deng; Jieqing Li; Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao; Zhaoxia Gao; Jay Vadgama; Yong Wu
Journal:  Biomed Pharmacother       Date:  2020-01-29       Impact factor: 7.419

Review 6.  Application of magnetic nanoparticles in nucleic acid detection.

Authors:  Congli Tang; Ziyu He; Hongmei Liu; Yuyue Xu; Hao Huang; Gaojian Yang; Ziqi Xiao; Song Li; Hongna Liu; Yan Deng; Zhu Chen; Hui Chen; Nongyue He
Journal:  J Nanobiotechnology       Date:  2020-04-21       Impact factor: 10.435

Review 7.  Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.

Authors:  Can-Bin Fang; Hua-Tao Wu; Man-Li Zhang; Jing Liu; Guo-Jun Zhang
Journal:  Front Cell Dev Biol       Date:  2020-04-02

8.  Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.

Authors:  Mingjun Zheng; Yuexin Hu; Rui Gou; Ouxuan Liu; Xin Nie; Xiao Li; Qing Liu; Yingying Hao; Juanjuan Liu; Bei Lin
Journal:  J Cell Mol Med       Date:  2020-01-29       Impact factor: 5.310

9.  Comparison of suspected Lynch syndrome patients carrying BRCA and BRCA-like variants with Lynch syndrome probands: Phenotypic characteristics and pedigree analyses.

Authors:  Yun Xu; Cong Li; Zhimin Wang; Fangqi Liu; Ye Xu
Journal:  Mol Genet Genomic Med       Date:  2020-06-16       Impact factor: 2.183

Review 10.  BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.

Authors:  Anbok Lee; Byung In Moon; Tae Hyun Kim
Journal:  Ann Lab Med       Date:  2020-03       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.